title: Improving clinical trials: American Society of Clinical Psychopharmacology recommendations.
abstract: The major purpose of this American Society of Clinical Psychopharmacology-sponsored meeting was to identify strategies for more efficiently detecting clinical drug effects, thus reducing the economic and scientific risks of investigating new chemical entities in psychiatric disorders. The meeting consisted of presentations and discussions by experts who repeatedly had difficulty pursuing scientific, public health--relevant goals. Many approaches to improving the detection of potentially beneficial agents were reviewed. In this article, we discuss technically feasible study improvements. The scope of inquiry included identifying means of shifting institutional and regulatory assumptions and processes, even to the point of seeking appropriate national incentives.
authors.affiliation: New York State Psychiatric Institute and Columbia University, Unit 22, 1051 Riverside Dr, New York, NY 10032, USA. dfk2@columbia.edu
authors.forename: Donald F
authors.initials: DF
authors.lastname: Klein
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
authors.forename: Jean
authors.initials: J
authors.lastname: Endicott
authors.forename: Lawrence
authors.initials: L
authors.lastname: Adler
authors.forename: Ira
authors.initials: I
authors.lastname: Glick
authors.forename: Amir
authors.initials: A
authors.lastname: Kalali
authors.forename: Steven
authors.initials: S
authors.lastname: Leventer
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Mattes
authors.forename: Peter
authors.initials: P
authors.lastname: Ross
authors.forename: Alexander
authors.initials: A
authors.lastname: Bystritsky
mesh_terms: D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000379:methods*; D004195:Disease Models, Animal; D004345:Drug Industry / Q000331:legislation & jurisprudence; D004989:Ethics; D006801:Humans; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D011619:Psychotropic Drugs